Agile Therapeutics, Inc. (AGRX) Q3 2022 Earnings Call Transcript

Nov. 07, 2022 6:59 PM ETAgile Therapeutics, Inc. (AGRX)
SA Transcripts profile picture
SA Transcripts
133.64K Followers

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET

Company Participants

Matthew Riley - Head of Investor Relations

Alfred Altomari - Chairman and Chief Executive Officer

Amy Welsh - Chief Commercial Officer

Jason Butch - Chief Accounting Officer

Conference Call Participants

Oren Livnat - H.C. Wainwright

Nazibur Rahman - Maxim Group LLC

Operator

Good afternoon, and welcome to the Agile Therapeutics Third Quarter 2022 Financial Results Conference Call. Please note that today’s event is being recorded.

I would now like to turn the conference over to Matt Riley, Head of Investor Relations.

Matthew Riley

Hello, everyone, and welcome to today’s conference call to discuss our third quarter 2022 financial results and corporate update.

Before we start, let me remind you that today’s call will include forward-looking statements based on our current expectations, including statements concerning our financial outlook and financing prospects for the future, our outlook for the fourth quarter of 2022, management’s expectations for our future financial and operational performance, including our expectations regarding the market growth of Twirla and our operating expenses, our business strategy, our partnership with Afaxys and its ability to promote growth, our product supply agreement with Nurx and its ability to educate patients about Twirla, our connected TV campaign and its ability to promote growth and our assessment of the combined hormonal contraceptive market generally, among other statements regarding our plans, prospects and expectations.

Such statements represent our judgments as of today, are not promises or guarantees and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Please refer to our filings with the SEC, which are available through the Investor Relations section of our website for information concerning risk factors that may affect the Company. We undertake no obligation to

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.